CR-001

DRUG2 trials

Sponsors

Crescent Biopharma Inc., Crescent Biopharma, Inc.

Conditions

Locally Advanced / Metastatic Solid TumorsLocally Advanced or Metastatic Solid Tumors

Phase 1

CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

RecruitingNCT07335497

Crescent Biopharma, Inc.Locally Advanced / Metastatic Solid Tumors

Start: 2026-02-17End: 2029-02-01Target: 290Updated: 2026-09-10

A Phase 1/2, Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamic, and Antitumor Activity of CR-001 in Adult Participants with Locally Advanced or Metastatic Solid Tumors.

Not yet recruitingCTIS2025-523590-42-00

Crescent Biopharma Inc.Locally Advanced or Metastatic Solid Tumors

Target: 78Updated: 2026-06-04

Related Papers

ASCEND: A phase 1/2, dose-escalation, optimization, and dose-expansion study to evaluate the safety and antitumor activity of CR-001 in adults with locally advanced or metastatic solid tumors.

Journal of Clinical Oncology2026-05-28